ClinicalTrials.gg
CompletedNCT00623623Updated Aug 1, 2019Results posted

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

A Phase 3 interventional study of primary PCI and enoxaparin in Myocardial Infarction, sponsored by Boehringer Ingelheim. Completed at 201 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,899
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.

Started
2008
the only one that year
Phase 3
6 of 12
none open now
Registered
3rd of 12
by date

Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is the only one that started in 2008, is one of 6 in phase 3, and was the 3rd registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Myocardial Infarction by Boehringer Ingelheim as a file.
02

Study summary

This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.

The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated.

All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age equal or greater than 18 years
  2. Onset of symptoms \< 3 hours prior to randomisation 3.12-lead indicative of an acute STEMI

4. received

Exclusion criteria

Exclusion criteria:

Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,899 participants (actual)

Study arms

  • Experimental
    Tenecteplase

    Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention

    Drug: enoxaparin · Procedure: catheterisation · Drug: tenecteplase · Drug: clopidogrel

  • Other
    primary PCI

    Standard primary PCI

    Procedure: primary PCI

Interventions

  • Procedureprimary PCI

    Standard primary PCI

  • Adjunctive treatment

  • Procedurecatheterisation

    Routine or rescue coronary intervention

  • Single, weight-adjusted i.v. bolus of tenecteplase

  • Adjunctive treatment

06

What researchers measure

Primary outcomes

  1. Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

    The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).

    Time frame: 30 days

Secondary outcomes

  1. Number of Patients With All Cause Mortality

    This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.

    Time frame: 30 days

  2. Number of Patients With Cardiac Mortality

    This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.

    Time frame: 30 days

  3. Number of Patients With Cardiogenic Shock

    This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.

    Time frame: 30 days

  4. Number of Patients With Congestive Heart Failure (CHF)

    This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.

    Time frame: 30 days

  5. Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

    This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported

    Time frame: 30 days

  6. Number of Patients With Rehospitalisation for Cardiac Reasons

    This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported

    Time frame: 30 days

  7. Number of Patients With Rehospitalisation for Non-cardiac Reasons

    This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported

    Time frame: 30 days

  8. Number of Patients With Serious Repeat Target Vessel Revascularization

    This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported

    Time frame: 30 days

  9. Number of Patients With All Cause Death and Shock

    This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported

    Time frame: 30 days

  10. Number of Patients With All Cause Death and Shock and CHF

    This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.

    Time frame: 30 days

  11. Number of Patients With All Cause Death and Shock and Reinfarction

    This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported

    Time frame: 30 days

  12. Number of Patients With Total Fatal Stroke

    This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported

    Time frame: 30 days

  13. Number of Patients With Total Disabling Stroke

    This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported

    Time frame: 30 days

  14. Number of Patients With Total Non-disabling Stroke

    This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported

    Time frame: 30 days

  15. Number of Patients With Intracranial Haemorrhage

    This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported

    Time frame: 30 days

  16. Number of Patients With Ischaemic Stroke

    This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported

    Time frame: 30 days

  17. Number of Patients With Total Stroke (All Types)

    This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported

    Time frame: 30 days

  18. Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

    This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported

    Time frame: 30 days

  19. Number of Patients With Minor Non-intracranial Bleeds

    This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported

    Time frame: 30 days

  20. Number of Patients With Total Non-intracranial Bleeds

    This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported

    Time frame: 30 days

  21. Number of Patients With Serious Resuscitated Ventricular Fibrillation

    This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported

    Time frame: 30 days

  22. Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

    This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported

    Time frame: 30 days

  23. Number of Patients With All Cause Death and Non-fatal Stroke

    This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported

    Time frame: 30 days

  24. Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

    This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported

    Time frame: 30 days

07

Results

Posted Aug 1, 2019

Participant flow

Open-label, prospective, randomised, parallel, comparative international multicentre trial

Participant flow — Overall Study
MilestoneTenecteplase (Group A)Primary PCI (Group B)
Started950949
Completed949948
Not completed11
Withdrew: Previous enrolment into this study11

Outcome measures

PrimaryNumber of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.116135
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.195 · Relative risk: 0.86 · 95% CI 0.68 to 1.08modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Mortality
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Mortality4342
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression · p = 0.904 · Relative risk: 1.03 · 95% CI 0.68 to 1.55modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Cardiac Mortality
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Cardiac Mortality3132
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.905 · Relative risk: 0.97 · 95% CI 0.60 to 1.58modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Cardiogenic Shock
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Cardiogenic Shock4156
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.120 · Relative risk: 0.73 · 95% CI 0.49 to 1.08modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Congestive Heart Failure (CHF)
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Congestive Heart Failure (CHF)5772
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.170 · Relative risk: 0.79 · 95% CI 0.57 to 1.11modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Recurrent Myocardial Infarction (Reinfarction)
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Recurrent Myocardial Infarction (Reinfarction)2321
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.758 · Relative risk: 1.10 · 95% CI 0.61 to 1.97modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Rehospitalisation for Cardiac Reasons
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Rehospitalisation for Cardiac Reasons4541
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.663 · Relative risk: 1.10 · 95% CI 0.73 to 1.66modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Rehospitalisation for Non-cardiac Reasons
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Rehospitalisation for Non-cardiac Reasons1911
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.148 · Relative risk: 1.72 · 95% CI 0.82 to 3.60modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Serious Repeat Target Vessel Revascularization
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Serious Repeat Target Vessel Revascularization12
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.572 · Relative risk: 0.50 · 95% CI 0.05 to 5.52modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Death and Shock
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Death and Shock5973
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poission Regression model · p = 0.207 · Relative risk: 0.81 · 95% CI 0.58 to 1.13modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Death and Shock and CHF
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Death and Shock and CHF100123
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poission Regression model · p = 0.100 · Relative risk: 0.81 · 95% CI 0.63 to 1.04modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Death and Shock and Reinfarction
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Death and Shock and Reinfarction7785
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poission Regression model · p = 0.511 · Relative risk: 0.91 · 95% CI 0.67 to 1.22modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Total Fatal Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Total Fatal Stroke74
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.369 · Relative risk: 1.75 · 95% CI 0.52 to 5.97modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Total Disabling Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Total Disabling Stroke20
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.168 · Relative risk: 4.99 · 95% CI 0.51 to 49.08modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Total Non-disabling Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Total Non-disabling Stroke81
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.049 · Relative risk: 8.02 · 95% CI 1.00 to 63.97modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Intracranial Haemorrhage
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Intracranial Haemorrhage92
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.054 · Relative risk: 4.51 · 95% CI 0.98 to 20.82modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Ischaemic Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Ischaemic Stroke63
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.324 · Relative risk: 2.00 · 95% CI 0.50 to 7.99modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Total Stroke (All Types)
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Total Stroke (All Types)155
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.032 · Relative risk: 3.01 · 95% CI 1.10 to 8.24modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions6145
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.111 · Relative risk: 1.36 · 95% CI 0.93 to 1.97modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Minor Non-intracranial Bleeds
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Minor Non-intracranial Bleeds206191
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.397 · Relative risk: 1.08 · 95% CI 0.91 to 1.28modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Total Non-intracranial Bleeds
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Total Non-intracranial Bleeds267236
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.107 · Relative risk: 1.13 · 95% CI 0.97 to 1.31modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Serious Resuscitated Ventricular Fibrillation
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Serious Resuscitated Ventricular Fibrillation3238
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.471 · Relative risk: 0.84 · 95% CI 0.53 to 1.34modified Poisson regression model with robust error variance
SecondaryNumber of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures1029
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.003 · Relative risk: 0.35 · 95% CI 0.17 to 0.71modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Death and Non-fatal Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Death and Non-fatal Stroke5043
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.451 · Relative risk: 1.17 · 95% CI 0.78 to 1.73modified Poisson regression model with robust error variance
SecondaryNumber of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke
ParticipantsTenecteplase (Group A)Primary PCI (Group B)
Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke117135
Statistical analysis
  • Tenecteplase (Group A) vs Primary PCI (Group B) · modified Poisson regression model · p = 0.220 · Relative risk: 0.87 · 95% CI 0.69 to 1.09modified Poisson regression model with robust error variance

Adverse events

Collected over From first drug administration until end of tiral, up to 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenecteplase (Group A)43/949 (4.5%)146/949 (15.4%)0/949 (0%)
Primary PCI (Group B)42/948 (4.4%)164/948 (17.3%)0/948 (0%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventTenecteplase (Group A)Primary PCI (Group B)
Ventricular fibrillationCardiac disorders41/94946/948
Cardiac arrestCardiac disorders10/94916/948
Atrioventricular blockCardiac disorders9/94914/948
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders11/94914/948
Ventricular tachycardiaCardiac disorders11/94913/948
Atrial fibrillationCardiac disorders4/94911/948
PericarditisCardiac disorders9/9497/948
Coronary artery occlusionCardiac disorders3/9498/948
PneumoniaInfections and infestations7/9495/948
Renal failure acuteRenal and urinary disorders3/9495/948

Baseline characteristics

Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).

Age, Continuous
Age, Continuous(Years)Tenecteplase (Group A)Primary PCI (Group B)Total
Mean60 ± 12.4260 ± 12.4960 ± 12.46
Sex: Female, Male
Sex: Female, Male(Participants)Tenecteplase (Group A)Primary PCI (Group B)Total
Female195208403
Male7547401494
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Tenecteplase (Group A)Primary PCI (Group B)Total
Count of participants——0
08

Study locations

201 sites
  • 1123.28.43009 Boehringer Ingelheim Investigational Site
    Salzburg, Austria
  • 1123.28.43010 Boehringer Ingelheim Investigational Site
    Salzburg, Austria
  • 1123.28.43001 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43002 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43003 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43004 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43005 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43007 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.43008 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1123.28.32060 Boehringer Ingelheim Investigational Site
    Bornem, Belgium
  • 1123.28.32010 Boehringer Ingelheim Investigational Site
    Bruxelles, Belgium
  • 1123.28.32070 Boehringer Ingelheim Investigational Site
    Herentals, Belgium
  • 1123.28.32040 Boehringer Ingelheim Investigational Site
    Liège, Belgium
  • 1123.28.55010 Boehringer Ingelheim Investigational Site
    Brasilia, Brazil
  • 1123.28.55020 Boehringer Ingelheim Investigational Site
    Brasilia, Brazil
  • 1123.28.55008 Boehringer Ingelheim Investigational Site
    Cabo Frio, Brazil
  • 1123.28.55017 Boehringer Ingelheim Investigational Site
    Campinas, Brazil
  • 1123.28.55007 Boehringer Ingelheim Investigational Site
    Porto Alegre, Brazil
  • 1123.28.55001 Boehringer Ingelheim Investigational Site
    Recife, Brazil
  • 1123.28.55018 Boehringer Ingelheim Investigational Site
    Rio de Janeiro, Brazil
  • 1123.28.55028 Boehringer Ingelheim Investigational Site
    Rio de Janeiro, Brazil
  • 1123.28.55016 Boehringer Ingelheim Investigational Site
    Sao Lourenço do Sul, Brazil
  • 1123.28.55004 Boehringer Ingelheim Investigational Site
    Sao Paulo, Brazil
  • 1123.28.55014 Boehringer Ingelheim Investigational Site
    Sao Paulo, Brazil
  • 1123.28.11006 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1123.28.11505 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1123.28.11002 Boehringer Ingelheim Investigational Site
    Newmarket, Ontario, Canada
  • 1123.28.13001 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.13002 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.13003 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.13004 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.13005 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.13006 Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • 1123.28.3376A Boehringer Ingelheim Investigational Site
    Ambérieu en Bugey, France
  • 1123.28.3329A Boehringer Ingelheim Investigational Site
    Aubervilliers Cedex, France
  • 1123.28.3329B Boehringer Ingelheim Investigational Site
    Aubervilliers Cedex, France
  • 1123.28.3329C Boehringer Ingelheim Investigational Site
    Aubervilliers Cedex, France
  • 1123.28.3351A Boehringer Ingelheim Investigational Site
    Besancon, France
  • 1123.28.3351B Boehringer Ingelheim Investigational Site
    Besancon, France
  • 1123.28.3315A Boehringer Ingelheim Investigational Site
    Besançon cedex, France
  • 1123.28.3315B Boehringer Ingelheim Investigational Site
    Besançon cedex, France
  • 1123.28.3302A Boehringer Ingelheim Investigational Site
    Bobigny, France
  • 1123.28.3302B Boehringer Ingelheim Investigational Site
    Bobigny, France
  • 1123.28.3319A Boehringer Ingelheim Investigational Site
    Bordeaux Cedex, France
  • 1123.28.3319B Boehringer Ingelheim Investigational Site
    Bordeaux Cedex, France
  • 1123.28.3319C Boehringer Ingelheim Investigational Site
    Bordeaux Cedex, France
  • 1123.28.3374A Boehringer Ingelheim Investigational Site
    Bourg en Bresse, France
  • 1123.28.3385A Boehringer Ingelheim Investigational Site
    Bourg en Bresse, France
  • 1123.28.3383A Boehringer Ingelheim Investigational Site
    Bourg-en-Bresse, France
  • 1123.28.3347A Boehringer Ingelheim Investigational Site
    Bourges, France
  • 1123.28.3347B Boehringer Ingelheim Investigational Site
    Bourges, France
  • 1123.28.3347C Boehringer Ingelheim Investigational Site
    Bourges, France
  • 1123.28.3355A Boehringer Ingelheim Investigational Site
    Bron, France
  • 1123.28.3355B Boehringer Ingelheim Investigational Site
    Bron, France
  • 1123.28.3382A Boehringer Ingelheim Investigational Site
    Caluire et Cuire, France
  • 1123.28.3311A Boehringer Ingelheim Investigational Site
    Châteauroux cedex, France
  • 1123.28.3311B Boehringer Ingelheim Investigational Site
    Châteauroux cedex, France
  • 1123.28.3346A Boehringer Ingelheim Investigational Site
    Châteauroux cedex, France
  • 1123.28.3346B Boehringer Ingelheim Investigational Site
    Châteauroux cedex, France
  • 1123.28.3303A Boehringer Ingelheim Investigational Site
    Clichy Cedex, France
  • 1123.28.3309A Boehringer Ingelheim Investigational Site
    Dreux, France
  • 1123.28.3342A Boehringer Ingelheim Investigational Site
    Dreux, France
  • 1123.28.3337A Boehringer Ingelheim Investigational Site
    Evecquemont, France
  • 1123.28.3387A Boehringer Ingelheim Investigational Site
    Fort De France Cedex, France
  • 1123.28.3388A Boehringer Ingelheim Investigational Site
    Fort De France Cedex, France
  • 1123.28.3353A Boehringer Ingelheim Investigational Site
    Grenoble, France
  • 1123.28.3353B Boehringer Ingelheim Investigational Site
    Grenoble, France
  • 1123.28.3317A Boehringer Ingelheim Investigational Site
    La Tronche, France
  • 1123.28.3317B Boehringer Ingelheim Investigational Site
    La Tronche, France
  • 1123.28.3339A Boehringer Ingelheim Investigational Site
    Le Chesnay Cedex, France
  • 1123.28.3339B Boehringer Ingelheim Investigational Site
    Le Chesnay Cedex, France
  • 1123.28.3307A Boehringer Ingelheim Investigational Site
    Le Chesnay, France
  • 1123.28.3336A Boehringer Ingelheim Investigational Site
    Le Port-Marly, France
  • 1123.28.3301A Boehringer Ingelheim Investigational Site
    Lille Cedex, France
  • 1123.28.3301B Boehringer Ingelheim Investigational Site
    Lille Cedex, France
  • 1123.28.3325A Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 1123.28.3325B Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 1123.28.3326A Boehringer Ingelheim Investigational Site
    Lille, France
  • 1123.28.3318A Boehringer Ingelheim Investigational Site
    Lyon cedex 3, France
  • 1123.28.3318B Boehringer Ingelheim Investigational Site
    Lyon cedex 3, France
  • 1123.28.3318C Boehringer Ingelheim Investigational Site
    Lyon cedex 3, France
  • 1123.28.3369A Boehringer Ingelheim Investigational Site
    Lyon cedex 4, France
  • 1123.28.3369B Boehringer Ingelheim Investigational Site
    Lyon cedex 4, France
  • 1123.28.3356A Boehringer Ingelheim Investigational Site
    Lyon cedex 7, France
  • 1123.28.3356B Boehringer Ingelheim Investigational Site
    Lyon cedex 7, France
  • 1123.28.3308A Boehringer Ingelheim Investigational Site
    Melun cedex, France
  • 1123.28.3308B Boehringer Ingelheim Investigational Site
    Melun cedex, France
  • 1123.28.3340A Boehringer Ingelheim Investigational Site
    Melun, France
  • 1123.28.3340B Boehringer Ingelheim Investigational Site
    Melun, France
  • 1123.28.3379A Boehringer Ingelheim Investigational Site
    Montelimar Cedex, France
  • 1123.28.3328A Boehringer Ingelheim Investigational Site
    Montfermeil, France
  • 1123.28.3328B Boehringer Ingelheim Investigational Site
    Montfermeil, France
  • 1123.28.3328C Boehringer Ingelheim Investigational Site
    Montfermeil, France
  • 1123.28.3349A Boehringer Ingelheim Investigational Site
    Nantes Cedex 1, France
  • 1123.28.3349B Boehringer Ingelheim Investigational Site
    Nantes Cedex 1, France
  • 1123.28.3313A Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1123.28.3313B Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1123.28.3322A Boehringer Ingelheim Investigational Site
    Nice cedex 1, France
  • 1123.28.3322B Boehringer Ingelheim Investigational Site
    Nice cedex 1, France
  • 1123.28.3322C Boehringer Ingelheim Investigational Site
    Nice cedex 1, France

Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc. 2016 Jun 13;5(6):e003559. doi: 10.1161/JAHA.116.003559. PubMed 28525886 ↗
  • Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. Heart. 2016 Apr;102(7):527-33. doi: 10.1136/heartjnl-2015-308075. Epub 2016 Jan 18. PubMed 26783237 ↗
  • Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015 Aug 24;4(8):e002049. doi: 10.1161/JAHA.115.002049. PubMed 26304934 ↗
  • Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 2015 May;101(9):692-8. doi: 10.1136/heartjnl-2014-306686. Epub 2015 Feb 17. PubMed 25691510 ↗
  • Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26. PubMed 25161043 ↗
  • Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014 Oct;100(19):1543-9. doi: 10.1136/heartjnl-2014-306023. Epub 2014 Jun 10. PubMed 24916050 ↗
  • Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10. PubMed 23473396 ↗
  • Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010 Jul;160(1):30-35.e1. doi: 10.1016/j.ahj.2010.04.007. PubMed 20598969 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in Sep 2012, 54 months.

Results were first posted in Aug 2019, 6 years 11 months after primary completion. A results delay was requested in Apr 2014.

Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Feb 26, 2008
StartActual
Mar 1, 2008
Primary completionActual
Sep 1, 2012
CompletionActual
Sep 1, 2012
Results delay requested
Apr 30, 2014
Results first posted
Aug 1, 2019
Last update
Aug 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00623623
Responsible party
Sponsor
First posted
Feb 26, 2008
Start date
Mar 1, 2008
Primary completion
Sep 1, 2012
Completion
Sep 1, 2012
Results posted
Aug 1, 2019
Last update
Aug 1, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion